Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -0.76%86 EBITDA Margin % is 37.68% as of Mar. 2026, which is 70% above its 10-year median of 22.14. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Procter & Gamble Health ranks better than 89.69% on this metric.
Procter & Gamble Health (BOM:500126) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Procter & Gamble Health EBITDA Margin % Related Terms
Procter & Gamble Health EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500126 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a EBITDA Margin % of 37.68% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Procter & Gamble Health and its competitors. This is 70% above median its historical median of 22.14. Over the past decade, Procter & Gamble Health's EBITDA Margin % has ranged from 6.87 to 33.67. According to the industry distribution chart, Procter & Gamble Health ranks #99 out of 960 companies in the Drug Manufacturers industry, placing it in the top 10.3%.
Is Procter & Gamble Health's EBITDA Margin % too high?
Procter & Gamble Health's current EBITDA Margin % of 37.68% is 70% above median its 10-year median of 22.14. Over the past 10 years, this metric has ranged from a low of 6.87 to a high of 33.67. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Procter & Gamble Health's value of 37.68% is 201.1% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #99 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #99 out of 960 companies for EBITDA Margin %. This places Procter & Gamble Health in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Procter & Gamble Health's value of 37.68% is 201.1% above this benchmark. Historically, Procter & Gamble Health's own EBITDA Margin % has ranged from 6.87 to 33.67 over the past decade. While the company's 10-year median is 22.14 vs. the industry median of 12.52, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current EBITDA Margin % of 37.68% is 201.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current EBITDA Margin % is 37.68%, which is 70% above median its own 10-year median of 22.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current EBITDA Margin % is 37.68%, which is 70% above median its 10-year median of 22.14 and 201.1% above the Drug Manufacturers industry median of 12.52. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current EBITDA Margin % is 37.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27.
GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.
Key valuation signals for BOM:500126:
EBITDA Margin %: 37.68% (70% above median its 10-year median of 22.14)
GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
Industry Position: 201.1% above the Drug Manufacturers median (#99 of 960)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
